Evaluation of the safety and efficancy in teneligliptin in type 2 diabetic patients with CKD

Evaluation of the safety and efficancy in teneligliptin in type 2 diabetic patients with CKD - Evaluation of the safety and efficancy in teneligliptin in type 2 diabetic patients with CKD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010098

Enrollment

Registered

2013-04-01

Start date

2013-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Taking the teneligliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients with CKD

Exclusion criteria

Exclusion criteria: Patients who are inappropriate to use teneligliptin

Design outcomes

Primary

Measure	Time frame
HbA1c	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026